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The role of older age in patients’ perceptions of the benefits and risks of medical treatments 
has hardly been empirically investigated. This study explored benefit-risk perception age 
differences between adults aged 65 years old and over (older group) and those aged 18-64 
years old (younger group). An online survey – representative for age, sex, and education – 
was conducted in Ohio, USA (N=1,520), and Germany (N=1,536). The results showed clear 
age differences that strongly support recent pilot findings. Older adults perceived prescription 
medicines – including their benefits, and effectiveness – significantly more positively than 
their younger counterparts. They were more likely to have significantly higher benefit and 
lower risk perceptions for most, but not all, medical treatments investigated. In forming these 
perceptions, older adults relied much more on positive/negative affect, that is, their positive/ 
negative experiences and feelings of “goodness” or “badness” they associated with each 
medicine, medical procedure, or test investigated. They also consistently perceived doctors 
and pharmacists as more competent and trustworthy. Contrary to popular belief, however; 
both age groups ranked their reliance on 15 different medical (e.g. doctors), societal (e.g. 
social media), and industry (e.g. pharmaceutical company websites) sources of medicines 
information remarkably similarly. Adults of all ages also were more likely to attribute the 
causes of side effects to patients over any other actor. The study concludes by emphasizing 
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Understanding how patients of all ages perceive the benefits and risks of medical treatments 
is vitally important. A wealth of research has demonstrated that benefit-risk perceptions can 
influence patients’ (1) medicine-taking behaviour such as their treatment choices and regimen 
compliance; (2) acceptability of adverse reactions; (3) attitudes towards medical, societal, and 
industry actors; and (4) information-seeking behaviour such as where to obtain medicines 
information and which sources to trust [1-9]. Benefit-risk perception knowledge can, in turn, 
inform pharmacovigilance interventions and is widely recognized as a pre-requisite for 
designing effective benefit-risk communication programs [3, 10-12]. Communicators, such as 
government regulators and patient advocacy groups, can, for example, design more effective 
tools, which can correct patients’ misconceptions, strengthen accurate beliefs, and add 
missing information that is “material” to decision-making [8, 13-14]. 
 
Age differences have received remarkably little attention in benefit-risk perception research 
[15]. The vast majority of early studies were confined to student samples or paid little 
attention to age. Thousands of more recent studies have either not reported age-related results 
or presented age as a confounder of a stronger relationship with another variable such as 
gender, risk beliefs, or trust [16]. Researchers have been more interested in other factors such 
as the characteristics of hazards (e.g. voluntariness, controllability, uncertainty), or 
characteristics of perceivers other than age (e.g. gender, race, nationality) [17-20]. While 
some medical studies have used older samples to examine adults’ benefit-risk perceptions, 
e.g. [21-22], far fewer have specifically investigated differences (and similarities) between 
older and younger adults [23]. This lack of age research is particularly surprising in the 
medical domain considering older adults consume the highest percentage of medicines by age 
group and are far more likely than their younger counterparts to have multiple chronic 
diseases such as hypertension, heart disease, and diabetes [24-26]. Indeed, older adults face a 
bewildering array of benefit-risk decisions about numerous medicines, medical procedures, 
and tests [27].  
 
Despite the dearth of benefit-risk perception studies, a burgeoning literature provides strong 
evidence that older age has a profound influence on individuals’ judgements and decision-
making [28-31]. For example, Mikels et al. [32] reviewed a raft of research identifying age-
related changes in cognition, emotion, and motivation across the lifespan. Finucane [33] 
suggests numerous ways that such findings might be relevant and applicable to benefit-risk 
perception and communication. Yet, beyond these constructive suggestions, few applied 
studies have been conducted outside of financial and automotive contexts [23, 30]. One 
exception is a recent medical domain pilot study [15] that identified clear benefit-risk 
perception differences between adults aged 58-93 years old (older group), and those aged 31-
50 years old (younger group). Amongst other results, older adults perceived greater risk today 
than 20 years ago compared to their younger counterparts and their quantitative benefit-risk 
judgements were influenced by the positive/ negative feelings they most associated with 
different medical treatments [15]. Taken together, these studies provide good reason to 
believe that older age has an influential effect on pharmaceutical benefit-risk perception. 
However, more extensive research is needed, including representative studies that can test the 




This study seeks to significantly contribute to understanding the role of older age in patients’ 
pharmaceutical benefit-risk perceptions. The primary goal was to test the generalizability of 
recent pilot findings in representative populations (see [15]). In particular, the study explored 
whether older versus younger adults are more likely to (1) associate medicines to their 
benefits and perceive them as effective; (2) trust their doctors and pharmacists, rate them 
highly, and rely on them as sources of medicines information; and (3) perceive lower risks 
and higher benefits from different medical treatments. Following recent decision-making age 
research [32], the study also examined whether older compared to younger adults rely more 






The data for this study originates from a representative online survey conducted from 21 
March to 7 May 2019 by Qualtrics, an online panel provider1. A random quota sample was 
obtained with 3,056 respondents from the US state of Ohio (hereafter, “Ohio”) (N=1,520), 
and Germany (N=1,536). The authors were resource-limited to surveying two geographic 
regions2. Ohio is a bellwether state, that is, a geographic region where the public’s political 
tendencies match in microcosm those of the wider US [34]. While the entire US population of 
over 325 million could have been sampled, choosing a particularly representative state 
enabled more in-depth and reliable age comparisons. Germany was chosen as one of the 
largest countries in Europe with the national regulator, the German Federal Institute for 
Drugs and Medical Devices (BfArM3), playing a particularly important role in EU 
pharmaceutical regulation [36]  
 
The sample was constrained to represent each population, Ohio and Germany, on distribution 
of sex, age, and educational attainment (Supplemental Table 1). Further information was 
collected on respondents’ home county in Ohio and Länder in Germany, income bracket, 
political ideology ranging from very liberal to very conservative, and job status, as well as 
several questions on medical insurance (e.g. Medicare eligibility in Ohio).  
 






18-24 years 10 10 8 8 
25-34 years 12 14 14 14 
35-44 years 14 13 14 13 
45-54 years 14 15 14 17 
55-64 years 16 15 17 15 
65-74 years 26 17 16 17 





                                                 
1 The study was approved by King College London’s Research Ethics Office (MRA-18/19-10710). 
2 It is hoped that future studies can test this study’s results in other geographic regions.  
3 In German: Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM).  
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An online questionnaire was modelled on survey instruments created by Balog-Way and 
Löfstedt [15] and Paul Slovic and colleagues [1-3]. Respondents took a median of 18 minutes 
to complete the survey.  
 
Part 1: Associations to prescription medicines. Respondents were shown the words 
‘Prescription Medicines’ three times. Each time they were asked to type the first thought or 
association that came to mind. They then indicated whether each association was negative, 
neutral, or positive. The so-called ‘continued associations’ technique is a “sensitive indicator 
of the imagery and meaning associated with people’s mental representations for a wide 
variety of concepts” (p82 [3]) and has been used in previous pharmaceutical benefit-risk 
perception studies (e.g. 15).  
 
Part 2: Sources of medicines information. Three questions were asked about various sources 
of prescription medicines information in order to investigate respondents’: 
1. Perceptions of doctors, pharmacists, regulatory authorities, pharmaceutical 
companies, and patients in making sure medicines are safe and effective; 
2. Trustworthiness of the same sources in providing advice on medicines; and 
3. Reliance on obtaining information on prescription medicines from medical (e.g. 
doctors, pharmacists), societal (e.g. patient advocacy groups, family and friends, 
social media), and industry (e.g. pharmaceutical companies) information sources4. 
 
Part 3: Effectiveness and side effects perceptions. Respondents were asked how often they 
believe (1) medicines work as intended for patients, and (2) patients experience unwanted 
effects/ side effects from medicines. They were then presented with a list of seven possible 
causes of side effects and asked how often they think each one is the cause. Each one related 
to either patients (e.g. the patient had insufficient information), the domestic healthcare 
system (e.g. the patient’s health plan restricted access to safer medicines), or the role of 
government regulators, doctors, or pharmacists. 
 
Part 4: Risk and benefit perceptions. Respondents were asked to rate the risks and then 
benefits of 18 medical treatments on a scale from 1 to 7 (Table 1). The questions can be 
categorized as general measures of benefit and risk perception (see Wilson et al. 2019). 
“Risk” and “benefit” were intentionally not defined, and respondents were left to interpret 
what the terms meant to them for each medical treatment. The items were 12 prescription or 
over the counter medicines, 2 vaccines, 2 medical procedures, and 2 medical tests (Table 2). 
A variety of items were chosen, and most have been used in previous risk perception surveys.   
 
Table 1: Risk and benefit perception questions 
Risks To what extent would you say that adults who are taking or undergoing this medical 
treatment are at risk of experiencing personal harm from it?’  (1 = they are not at risk; 7 
= they are very much at risk) 
Benefits In general, how beneficial do you consider this treatment to be? (1 = not at all 
beneficial; 7 = very beneficial).  
 
Table 2: Eighteen medical treatments 
Medicines to treat depression Vitamin pills 
Medicines to treat Alzheimer’s Disease Blood pressure medicines 
Medicines to treat erectile dysfunction MMR vaccine 
                                                 
4 Medical, societal, and industry medicines information source categories were previously identified in multi-
national surveys [9].  
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Antibiotics Flu vaccine 
Sleeping pills Allergy medicines 
Herbal medicines Heart surgery 
Cancer chemotherapy Medical X-rays 
Insulin Prostate screening tests 
Medicines for cholesterol (e.g. statins) Acupuncture 
 
Part 5: Affective imagery. One further question sought to measure the positive/ negative 
affect that respondents attach to the same 18 medical treatments (Table 2). ‘Affect’ is defined 
as “the experience (with or without consciousness) of “goodness” or “badness” associated 
with external events and objects or internal representations (e.g. memories)” [33, 36]. 
Research dating to at least the 1960s has consistently shown the importance of affect (and 
emotion) in risk and benefit perception [37]. Moreover, age research strongly suggests that 
older adults are particularly reliant on affective processes in decision-making [32, 38], 
including recent prescription medicines studies [15]. The authors therefore deliberately 
sought to capture affective dimensions of respondents’ perceptions. 
 
To measure affect, respondents were asked to type the first feeling that comes to mind when 
thinking about 18 medical treatments. They then rated each feeling on a scale from 1 (very 
negative) to 7 (very positive). This enabled the authors to quantitatively measure the positive/ 
negative affective imagery or positive/ negative feelings of ‘goodness’ or ‘badness’ that 




Results were analysed using SPSS. To examine age differences, two groups were defined: (1) 
“younger” respondents aged 18-64 years old; and (2) “older” respondents aged 65 years old 
and over. Although a variety of age group delineations have been used previously (Finucane, 
2008; Hess et al. 2015), the 65+ “older” age group was chosen as it corresponds with specific 
socio-economic and medicines-related milestones in both the US and Germany (e.g. 
retirement, Medicare eligibility). The analysis predominantly relies on chi-square tests on 
crosstabs, independent samples t-tests, and correlations to examine differences between the 




(3.1) Positive and negative affect 
 
Respondents gave a total of 9,168 spontaneous associations to the term “Prescription 
Medicines”. Older vs. younger adults were significantly more likely to make positive 
associations to the stimulus in both Ohio (+8% more older adults; 45% older vs. 37% 
younger) and Germany (+25%; 44% vs. 19%) (p<0.001 on a chi-square test in both Ohio [Phi 
= 0.11] and Germany [Phi = 0.17]).  
 
Respondents were later asked to indicate the first feeling or emotion that comes to mind when 
thinking about 18 specific medical treatments (Table 2). A total of 42,958 spontaneous 
associations were made. After typing each association, a rating was provided on a scale from 
1 (very negative) to 7 (very positive). The geometric mean was calculated for all treatments 
and ranged from 4.97 (older adults and insulin) to 2.97 (older adults and sleeping pills) 




Age differences were calculated by subtracting older and younger respondents’ geometric 
mean ratings (Figure 1). Crucially, older adults were significantly more likely to make 
positive associations to 8/18 medical treatments (p<0.05 in an independent samples t-test): 
the flu vaccine (+0.82 difference between older vs. younger adults), heart surgery (+0.81), 
insulin (+0.76), antibiotics (+0.70), blood pressure medicines (+0.66), medical x-rays 
(+0.47), cancer chemotherapy (+0.42), and the MMR vaccine (+0.41). Older adults were only 
significantly more likely to rate sleeping pills less positively (-0.21 difference). No 
statistically significant age differences were found for the remaining 9/18 treatments.  
 
 
Figure 1: Geometric mean for older and younger adults positive/ negative associations to 18 medical treatments 
(1 = Very Negative; 7 = Very Positive).  
 
(3.2) Medicines information sources 
 
Respondents rated five key medical actors in making sure prescription medicines are safe and 
effective on a 5-point scale from excellent to poor. Prescribing doctors and pharmacists 
topped the list with 80% rating both as either excellent, very good, or good. Around two-
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(69%), and the US Food and Drug Administration (FDA) (66% of Ohio population) as at 
least good. Pharmaceutical companies were rated lowest with 59% indicating they are at least 
good in ensuring medicines as safe and effective.  
 
In both Germany and Ohio, older vs. younger adults were significantly more likely to rate 
prescribing doctors (+11% Ohio and +10% Germany more older adults) and pharmacists 
(+12% Ohio and +9% Germany), as at least good in ensuring that prescription medicines are 
safe and effective (p<0.05 on a chi-square test). The Phi values (effect sizes) indicated that 
age differences explained at least 15% of the variation in ratings of doctors and pharmacists 
in both regions. No significant age differences were found in both Germany and Ohio 
between respondents’ ratings of pharmaceutical companies, the FDA, BfArM, or patients.   
 
Respondents were then asked to rate the trustworthiness of the same information sources in 
providing medicines advice. At the top of the list again, doctors (3.79 mean on the five-point 
scale) and pharmacists (3.77) were rated as the most trustworthy sources. This was followed 
by patients taking prescription medicines (3.27), the FDA in Ohio (3.25), and BfArM in 
Germany (3.18). Out of all five actors, pharmaceutical companies (2.92) were rated as the 
least trustworthy source of medicines information. 
 
Similar to respondents’ ratings of actors in ensuring medicines are safe and effective, older 
vs. younger adults in both Ohio and Germany were significantly more likely to rate 
prescribing doctors (+0.14) and pharmacists (+0.11) as more trustworthy (Figure 2). In 
contrast, older adults were significantly more likely to rate pharmaceutical companies (-0.28) 
and especially BfArM (-0.52) as less trustworthy than their younger counterparts. No 
significant differences were found between older and younger adults’ trustworthiness of 
‘patients taking prescription medicines’ or ‘the FDA’.  
 
 
Figure 2: Older vs. younger adults’ trustworthiness of 6 actors in providing medicines advice. *FDA and BfArM 
were only surveyed in Ohio (N=1,520) and Germany (N=1,536), respectively. 
 
Respondents were asked to rank the five sources they rely on most for information on 


















Doctors Pharmacists Patients FDA* BfArM* Pharmaceutical
companies
Younger (18-64) Older (65+)
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provided at least one rank and a total of 13,166 ranks were made. Overall, the top five most 
highly ranked sources were: doctors (Ranked #1), pharmacists (2), family and friends (3), 
specific government regulators (BfArM and FDA combined) (4), and internet search engines 
(5). The lowest ranked sources, that the fewest respondents selected in their top five, were 
Internet websites other than search engines (10), television (11), social media (e.g. Facebook, 
Twitter) (12), national newspapers (including their websites) (13), local newspapers 
(including their websites) (14), and, at the bottom of the list, the radio (15).  
 
Notably, the rank ordering for older and younger respondents was remarkably similar (Table 
3). Nevertheless, in Ohio older vs. younger adults were significantly more likely to rate 
doctors (29% vs. 20%) and pharmacists (25% vs. 15%) in their top three medicines 
information sources (p<0.05 on a chi-square test). Similarly, in Germany older vs. younger 
adults were significantly more likely to rate doctors (28% vs. 18%) and pharmacists (23% vs. 
15%) in their top three (p<0.05 on a chi-square test) (Supplemental Table 2).  
 
Table 3: Older vs. younger adults combined ranking of medicines information sources they rely on most.   
Younger 
(18-64) 
Older (65+) All 
My doctor 1 1 1 
My pharmacist 2 2 2 
Family and friends (medically qualified or not) 3 5 3 
Specific government regulators (FDA/ BfArM combined) 5 3 4 
Internet search engines 4 4 5 
Medical journals 6 6 6 
Patient advocacy groups (including their websites) 8 7 7 
Pharmaceutical companies (including their websites) 7 8 8 
Pharmaceutical regulatory agencies (in general) 11 9 9 
Other Internet websites 9 10 10 
Television 10 11 11 
Social media (e.g., Facebook, Twitter) 12 13 12 
National newspapers (including their websites) 14 12 13 
Local newspapers (including their websites) 13 14 14 
Radio 15 15 15 
 
(3.3) Effectiveness and side effects perceptions 
 
Respondents were asked three related questions on their perceptions of the effectiveness and 
side effects of prescription medicines. First, the large majority (77%) believe that medicines 
work as intended for patients at least often (Table 4). In both Ohio and Germany, Older 
(83%) vs. younger (67%) adults were significantly more likely to perceive medicines as 
effective (+16% more older adults). The p-value on a chi-square test was significant at 
p<0.001 in both populations (Phi = 0.23 for Ohio and 0.25 for Germany).  
 
Second, the majority (58%) also believe that side effects occur only occasionally, rarely, or 




Third, respondents were asked about 8 possible explanations for why side effects occur 
(Figure 3). The three most frequently perceived causes all related to patients. A large number 
of respondents perceived patients ‘not following instructions’ (54%), ‘having insufficient 
information’ (45%), and ‘being unusually sensitive to the medicine’ (42%) as always, very 
often, or often the cause.  This was followed by the patient’s health plan restricting access to 
medicines (35%) and a lack of government regulation (33%). In contrast, the majority 
perceived pharmacists making mistakes (89%) and doctors prescribing the wrong dosage 
(81%) as only occasionally, rarely, or never being the cause of side effects.  
 
Corresponding with perceptions of key information sources (section 3.2), older vs. younger 
adults were significantly less likely to perceive doctors prescribing the wrong dosage and 
pharmacists making mistakes as a frequent cause of side effects (p<0.05 on a chi-square test) 
(Figure 3). In contrast, older adults were significantly more likely than their younger 
counterparts to attribute the causes of side effects to ‘patients not following instructions’.  
 
Table 4: Older and younger respondents’ perceptions of prescription medicines’ effectiveness and side effects.  













Always 4 2 3 3 2 3 
Very often 24 37 32 15 14 15 
Often 39 44 42 25 25 25 
Occasionally 24 13 17 39 48 45 
Rarely 7 2 4 15 10 11 
Never 3% 1% 2% 4% 1% 2% 
 
 
Figure 3: Bar chart showing how often older vs. younger respondents think side effects are caused by various 
explanations. 
 





























































The geometric mean was calculated for respondents’ risk ratings for all 18 medical treatments 
(Supplemental Table 3). On a scale from 1 (they are not at risk) to 7 (they are very much at 
risk), four medical treatments with the greatest perceived risk were cancer chemotherapy 
(4.68), heart surgery (4.54), sleeping pills (4.25) and medicines to treat depression (4.09). 
Treatments with the lowest perceived risk were prostate screening tests (2.86), herbal 
medicines (2.65), acupuncture (2.39) and vitamin pills (2.39), which all scored a mean 
average of less than 3.00.  
 
The geometric mean also was calculated for respondents benefit ratings (Supplemental Table 
3). On a scale from 1 (not at all beneficial) to 7 (very beneficial), two treatments scored a 
mean average of over 5.00: insulin (5.11) and heart surgery (5.08). A further 11 treatments 
recorded a mean benefit rating of over 4.00, including: antibiotics (4.94), blood pressure 
medicines (4.87) and medical X-rays (4.86). Vitamin pills (3.90), acupuncture (3.84), herbal 
medicines (3.80), medicines to treat erectile dysfunction (3.78), and, at the very bottom of the 
list, sleeping pills (3.68) all received a mean average of less than 4.00.  
 
Mean risk and benefit ratings were plotted onto a factor space (Figure 4). The plot quickly 
shows that perceptions of over half of all treatments surveyed (10/18) clustered together and 
were perceived as high benefit and low risk (top left quadrant). Three treatments were 
perceived as high benefit and high risk: heart surgery, cancer chemotherapy, and medicines to 
treat depression (top right quadrant). Acupuncture, vitamin pills, herbal medicines, and 
erectile dysfunction medicines were all perceived as low benefit and low risk (bottom left 
quadrant). Finally, sleeping pills were the only treatment considered low benefit and high risk 
(bottom right quadrant).  
 
Age differences were calculated by subtracting younger adults mean risk and benefit ratings 
from older adults mean risk and benefit ratings, respectively. In both Ohio and Germany, 
older vs. younger adults perceived 7/18 treatments as significantly less risky (p<0.05 for chi-
square test): acupuncture (-0.49), flu vaccine (-0.35), blood pressure medicines (-0.25), 
vitamin pills (-0.24), prostate screening tests (-0.23), MMR vaccine (-0.19), and insulin (-
0.12). This was the only direction in which a significant relationship was found for 
respondents’ risk perceptions. 
 
In both Ohio and Germany, older vs. younger adults also perceived 8/18 treatments as 
significantly more beneficial (chi-square p-value < 0.05): flu vaccine (+0.75), heart surgery 
(+0.67), insulin (+0.64), antibiotics (+0.64), blood pressure medicines (+0.60), medical X-
rays (+0.40), medicines for cholesterol (+0.39), and the MMR vaccine (+0.34). Again, in 
both Ohio and Germany this was the only direction in which a significant relationship was 
found for respondents’ benefit perceptions.  
 
Medical treatments with a combined benefit and risk age difference of more than 0.50 were 
plotted onto a second factor space (Figure 5). These were the flu vaccine (1.09), blood 
pressure medicines (0.85), insulin (0.76), heart surgery (0.75), antibiotics (0.70), acupuncture 
(0.66), the MRR vaccine (0.53), and prostate screening tests (0.52). Notably, older vs. 
younger adults perceived all but three of these treatments – heart surgery, antibiotics, and 
acupuncture –as both significantly less risky and significantly more beneficial.    
 




Correlations between respondents’ positive/ negative affect scores (section 3.1) and risk and 
benefit perceptions (section 3.5) were examined for all 18 medical treatments (Supplemental 
Table 4). First, there was a greater correlation between older vs. younger adults’ risk 
perceptions and positive/negative affect in both Ohio and Germany for 10/18 treatments: 
medicines for erectile dysfunction, antibiotics, sleeping pills, herbal medicines, medicines for 
cholesterol, blood pressure medicines, flu vaccine, allergy medicines, prostate screening tests, 
and acupuncture (Supplemental Table 4). For the other eight medical treatments, there is no 
case in which both the Ohio and German samples show affect as more important for risk 
perceptions in the younger sample.  The reason is that for these eight medical treatments, we see 
mixed effects (e.g., for vitamin pills, younger adults in Ohio have a stronger relationship between 
affect and risk perceptions than older adults in Ohio do, but the relationship is reversed in 
Germany). Second, there was also a greater correlation between older vs. younger adults’ 
benefit perceptions and positive/ negative affect scores in both Ohio and Germany for 16/18 
medical treatments (Supplemental Table 4). Medical x-rays and acupuncture were the only 
two medical treatments for which this was not true. Taken together, older vs. younger adults 
were found to rely more on positive/ negative affect to inform their benefit and risk 
perceptions for most medical treatments surveyed. 
 
 
Figure 4: Respondents’ benefit-risk ratings for 18 medical treatments. MMR = Mumps Measles and Rubella 
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Figure 5: Older and younger respondents’ combined benefit and risk ratings for 8 medical treatments that had a 
0.50 or larger combined benefit-risk perception age difference. Circle = Older respondents; Triangles = Younger 
Respondents.  
 
 (4.) Discussion 
 
This study investigated age differences in adults’ pharmaceutical benefit-risk perceptions. By 
conducting a representative survey in the USA and Germany, the results show clear and 
significant differences between adults aged 18-64 years old (younger group) and those aged 
65 years and older (older group), which strongly supports recent pilot findings [15].  
 
(4.1) Benefits and effectiveness perceptions 
 
The cross-sectional survey revealed that older adults from the USA and Germany perceive 
prescription medicines – including their benefits and effectiveness – significantly more 
positively than their younger counterparts. Older adults were significantly more likely to (1) 
associate prescription medicines to positive mental representations (section 3.1), and (2) 
perceive that medicines work as intended at least often (section 3.3). Older adults also were 
significantly likely to perceive 8/18 specific medical treatments as more beneficial, with all 
10 other items surveyed having no observed benefit perception age differences (section 3.4).   
 
One reason for these clear age differences may well be that adults from the USA and 
Germany aged 65 years and over (older group) consume considerably more medicines than 
those aged 18-64 years (younger group) [25, 26, 39]. Martin et al. [25] found that 85% of US 
adults aged 60 years and older used at least one prescription medicine over a 30-day period in 
2015-2016, compared to 47% aged 20-59 years old. Similarly, 86% of adults aged 65 years 
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period in 20145, compared to 43% aged 15-64 years old [26]. Greater use means that older 
adults gain more therapeutically, which is likely to contribute to their more positive 
prescription medicines’ perceptions for relevant treatments. For example, the five survey 
items with the largest benefit perception age differences – the flu vaccine, heart surgery, 
insulin, antibiotics, and blood pressure medicines – are all more beneficial for older adults at 
the population level. While older adults are at higher risk of influenza complications [40], 
they also have a higher prevalence of heart disease, high blood pressure, and diabetes [24, 41-
42]. In contrast, no significant benefit perception age differences were found for herbal 
medicines, acupuncture, vitamin pills, medical X-rays, or allergy medicines, all of which 
arguably have similar benefits for adults of all ages. 
 
(4.2) Risk perceptions 
 
In comparison with respondents’ benefit perceptions (section 4.1), the survey revealed that 
older adults had significantly lower risk perceptions for 7/18 treatments, with no significant 
age differences identified for all 11 other items. Interestingly, only 4 of these treatments – flu 
vaccine, blood pressure medicines, insulin, and the MMR vaccine – were perceived as both 
significantly less risky and more beneficial by older adults. This suggests that, although 
perceived benefit and perceived risk are inversely related [3], age influences benefit and risk 
judgements differently [15].  
 
The results also compare well with several past studies that found older adults perceive lower 
risk for a wide variety of hazards and technologies [16, 43-44], including medical treatments 
[15]. Yet, significant risk perception age differences were not found for all items surveyed 
(section 3.4). Older versus younger adults therefore do not necessarily perceive greater or less 
risk in general. Indeed, other studies show that older adults perceive significantly greater risk 
for various technological, social, and natural hazards [45-47]. Further, Hanoch et al. [23] 
conducted a cross-sectional study with 317 adults aged 20-77 and found no significant age 
differences in medical risk-taking tendencies. This variety of findings provide strong 
evidence that age-related influences on risk perceptions vary depending on several currently 
unexamined contextual factors such as risk domain or type of hazard [23]. The present study 
goes further by finding that, even within the medical domain, the risks of various treatments 
are perceived differently by older and younger adults. As more evidence accumulates, a 
fruitful new line of inquiry would be to investigate these contextual factors more 
comprehensively and better understand under what conditions and for which hazards/ 
technologies/ medical treatments older versus younger adults perceive greater or less risk 
[15].  
 
(4.2) Reliance on the affect heuristic 
 
When combining older and younger adults’ benefit and risk perceptions, a remarkably 
familiar pattern was found (Figure 4). Most medical treatments (10/18) were perceived as low 
risk and high benefit. A second group – vitamin pills, herbal medicines, acupuncture, and 
erectile dysfunction medicines – were also perceived as low risk but with distinctly lower 
benefits. Three other items – heart surgery, cancer chemotherapy, and medicines for 
depression – were perceived as high risk and high benefit. Finally, only one item – sleeping 
pills – was perceived as both high risk and low benefit. These groupings are highly consistent 
with comparable survey research conducted in Canada, Sweden, the USA, and Ireland [1-3, 
                                                 
5 Data for the year 2019 are expected in mid-2020.  
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15]. In particular, respondents had remarkably similar benefit-risk perceptions for almost all 
medical treatments surveyed in both the present study and Slovic et al.’s [3] 2007 study of 
US adults (N=2,071). One particularly notable exception, however; was the marked reduction 
between 2007 and 2018 of perceived benefit for vitamin pills, the flu vaccine, and the MMR 
vaccine (see [3] p95). Although Slovic et al. [3] specified ‘vaccines’ more generally than ‘the 
flu vaccine’ or ‘the MMR vaccine’, research shows that adults’ acceptance of vaccines has 
wavered in the USA and Europe [48-49].  
 
Moreover, older adults’ benefit-risk perceptions were found to be more greatly correlated 
with measures of affect (section 3.5). Specifically, for most medical treatments, a greater 
correlation was found between older adults’ affective imagery and both their risk perceptions 
and benefit perceptions. In this context, the affect heuristic refers to patients’ reliance on the 
specific feelings of “goodness” or “badness” they associate with a given medical treatment 
[36, 50-51]. An array of past studies has demonstrated that perceived risk and perceived 
benefit of an activity (e.g. medicines taking) are linked to the strength of the positive or 
negative affect associated with that activity [50-54]. Affect guides benefit-risk perceptions 
with more positive affect associated with lower risks and higher benefits and, inversely, more 
negative affect associated with higher risk and lower benefit [36]. Crucially, recent 
judgement and decision-making research demonstrates that adults rely more on positive/ 
negative affect as they age [32, 38]. The present study therefore strongly supports these 
findings by showing that older adults rely more on positive/ negative affect when forming 
their benefit-risk perceptions [cf. 33]. It was particularly striking to find that older adults’ 
positive/ negative affect scores were significantly more correlated to perceived benefit for 




(4.3) Trust in doctors and pharmacists 
 
This study supports growing evidence that older versus younger adults are consistently more 
positive about prescribing doctors and pharmacists [15, 55-56]. Older adults were found to be 
significantly more likely to rate prescribing doctors and pharmacists highly, perceive them as 
more trustworthy, and rely on them as sources of prescription medicines information (section 
3.2). Although younger adults still rated doctors and pharmacists favorably, there is now clear 
evidence that older adults are much more positive about these two key medical actors.  
 
Age differences in the information sources patients trust, rate as competent, and rely on is 
fundamentally important for ensuring the safe and effective use of medicines [6, 57]. High 
trust contributes towards patient satisfaction, adherence to treatment, and improved health 
outcomes [58-60]. For example, a large cross-sectional survey [9] conducted in 6 European 
countries (N=6,001) found strong associations between patients’ perceived trustworthiness of 
medical actors, such as doctors and pharmacists, and their behavioral intentions. Higher trust 
in medical sources such as doctors and pharmacists were particularly strongly associated with 
patients adopting recommended medicine-taking behavior and seeking more information if 
they believed something was wrong with their medicine [9]. If, as this study shows, older 
adults perceive doctors and pharmacists as more trustworthy, then one would expect older 
adults to adopt more positive medicine-related behavior. Younger adults would, inversely, be 
expected to adopt less positive behavior. This raises important unanswered questions about 
why these age differences exist. Will younger adults perceive their doctors and pharmacists 
as more trustworthy as they grow older, or do these findings signal ingrained and enduring 
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inter-generational differences between today’s older and younger generations? Answering 
these questions call for future longitudinal studies. 
 
(4.4) Notable similarities 
 
While the main aim of this study was to identify age differences, the results also revealed at 
least two notable similarities. One is that adults of all ages relied on very similar sources of 
prescription medicines information (section 3.2). While doctors and pharmacists topped the 
rankings, sources such as social media, newspapers, and the radio ranked the lowest. One 
implication is that, although older adults perceive doctors and pharmacists as more 
trustworthy and rate them more highly (section 4.3), adults of all ages in the USA and 
Germany still rely on them the most [6, 9]. A second implication is that, perhaps surprisingly, 
adults of all ages have a comparably low reliance on social media, local and national 
newspapers, and the radio, which have starkly different uptakes by different generations. It is 
well-known that older adults are more likely to listen to the radio and buy broadsheet 
newspapers, and less likely to use the Internet, own a smartphone, and use social media [61-
64]. For example, Anderson and Perrin [63] found that in 2016 only 34% of US adults aged 
65 years and over ever use social networking sites such as Facebook or Twitter compared to 
69% aged 18 years and older, even though social media use has substantially increased in 
older US populations over the past 15 years. The results therefore demonstrate a crucial 
difference between (1) the sources that adults rely on most when seeking prescription 
medicines information (i.e. doctors, pharmacists) and (2) the varying channels they use to 
consume information in general– whether they receive medicines-related information or not 
(e.g. social media, the radio, newspapers) [65-67]. 
 
A second notable similarity was that adults of all ages are more likely to attribute the causes 
of side effects to patients than any other actor surveyed (section 3.2). This includes patients 
not following instructions, having insufficient information, and being unusually sensitive to 
medicines (Figure 3). Slovic et al. [3] and Balog-Way and Löfstedt [15] both reported similar 
findings. These findings together suggest that respondents’ perceptions of side effects are 
highly susceptible to fundamental attribution bias, “the tendency to overestimate the degree 
to which an individual’s behavior is determined by his or her abiding personal characteristics, 
attitudes, or beliefs and, correspondingly, to minimize the influence of the surrounding 
situation on that behavior” [68]. Adults of all ages tended to attribute the causes of side 
effects more to patients and less to other situational factors such as the role of governments, 
the healthcare system, doctors, and pharmacists. Individualistic Western cultures (e.g. the 
USA and Germany) compared to collectivistic East Asian cultures (e.g. Japan, Korea, China) 
also tend to focus their attributions more on the individual person [69-70], although see [71]. 
Future research therefore should investigate whether adults from collectivistic countries 
attribute the causes of side effects less to patients and more to the situation surrounding 
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Supplemental Table 1: Respondents’ sex, age, job status and educational attainment.   
Ohio Germany 
Sex (%) Male 47 50 
 
Female 52 50 
 
Other / prefer not to say 1 0 
Age (%) 18-64 66 67 
 
65+ 34 33 
Job status (%) Working full time 28 35 
 
Working part time 12 13 
 
Retired 34 38 
 
Unemployed (looking for work) 8 4 
 
Full-time Homemaker with no outside employment 10 6 
 




Other 6 3 
Ohio Education 
(%) 
Some schooling completed / No high school diploma 7 - 
 High school graduate or equivalent 35 - 
 Some college / no degree 22 - 
 Associate degree 8 - 
 Bachelor's degree 18 - 
 Graduate or professional degree 10 - 
Germany 
Education (%) 
No schooling or vocational training - 1 
 Secondary school without completed vocational training (POS 
8 classes) 
- 5 
 Secondary school with completed vocational training (POS 8 
classes) 
- 12 
 Middle school, secondary school without Abitur (POS 10 
classes) 
- 39 
 Abitur, university entrance qualification (EOS, 12 classes) - 18 
 University, technical college, polytechnic, technical college - 24 
 Scientific doctorate - 2 
 
Supplemental Table 2: Relative frequency with which a source was listed as one of a respondent’s top three 
sources they relied on for medicines information.  
Ohio Germany 
  Younger (%) Older (%) Younger (%) Older (%) 
Doctors 65.9 84.6 62.4 84.1 
Pharmacists 50.2 72.9 52.9 69.5 
Family and friends 31.2 20.5 37.5 22.7 
Internet search engines 30.3 27.6 26.3 14.9 
FDA / BfArM 25.9 21.5 25 21.3 
Medical journals 19 10.6 21.5 23 
Pharma. companies 18.6 11.1 16.8 11.6 
Patient advocacy groups 16.2 8.7 18.3 18.1 
Social media 15.7 3.6 14.4 4.8 
Television 15.1 7 16.9 7.6 
Other Internet websites 14.5 9.2 17.8 6.2 
Radio 11.7 3.6 12.8 4.2 
National newspapers 11.4 2.5 10.9 5.7 
Local newspapers 10.7 3.5 13.7 4.9 
 
Supplemental Table 3. Mean risk and benefit perception  
RISK PERCEPTIONS BENEFIT PERCEPTIONS 
Younger Older All Younger Older All 
Medicine to treat depression 4.06 4.11 4.09 4.20 4.45 4.37 
Medicines to slow the 
progression of Alzheimer’s 
disease 
3.61 3.54 3.56 4.16 4.37 4.29 
Medicines to treat erectile 
dysfunction (e.g. Viagra) 
3.62 3.76 3.71 3.75 3.80 3.78 
Antibiotics 3.57 3.51 3.53 4.57 5.20 4.94 
Sleeping pills 4.08 4.37 4.25 3.77 3.63 3.68 
Herbal medicines 2.67 2.64 2.65 3.80 3.79 3.80 
23 
 
Cancer chemotherapy 4.62 4.75 4.68 4.39 4.67 4.56 
Insulin 3.43 3.31 3.35 4.78 5.42 5.11 
Medicines for cholesterol 
(e.g. statins) 
3.54 3.45 3.48 4.16 4.55 4.42 
Vitamin pills 2.55 2.30 2.39 3.96 3.87 3.90 
Blood pressure medicines 3.83 3.57 3.66 4.55 5.14 4.87 
MMR vaccine 3.38 3.19 3.26 4.28 4.62 4.50 
Flu vaccine 3.39 3.04 3.17 3.86 4.60 4.24 
Allergy medicines 3.20 3.21 3.21 4.49 4.74 4.66 
Heart surgery 4.50 4.57 4.54 4.74 5.41 5.08 
Medical x-rays 3.57 3.49 3.52 4.54 4.94 4.86 
Prostate screening tests 3.00 2.77 2.86 4.47 4.77 4.73 
Acupuncture 2.72 2.22 2.39 3.74 3.91 3.84 
 
Supplemental Table 4: Correlations between valence of word associations with 18 medical treatments and 
corresponding perceptions of (1) risk and (2) benefit.   
 RISK PERCEPTIONS BENEFIT PERCEPTIONS 
Ohio Germany Ohio Germany 
Younger Older Younger Older Younger Older Younger Older 
Medicines for 
depression 









0.00 -0.27 -0.16 -0.25 0.40 0.48 0.28 0.46 
Antibiotics -0.21 -0.24 -0.05 -0.16 0.39 0.44 0.33 0.44 
Sleeping pills -0.23 -0.26 -0.06 -0.17 0.41 0.44 0.25 0.38 
Herbal 
medicines 
-0.09 -0.23 -0.11 -0.23 0.45 0.53 0.41 0.46 
Cancer 
chemotherapy 
-0.08 -0.28 -0.18 -0.16 0.28 0.44 0.26 0.33 




-0.21 -0.39 -0.06 -0.17 0.39 0.55 0.27 0.43 
Vitamin pills -0.19 -0.17 0.00 -0.15 0.42 0.51 0.36 0.48 
Blood pressure 
medicines 
-0.17 -0.30 -0.08 -0.14 0.36 0.47 0.31 0.48 
MMR vaccine -0.30 -0.40 -0.22 -0.16 0.50 0.55 0.37 0.42 
Influenza 
vaccine 
-0.29 -0.47 -0.27 -0.39 0.51 0.65 0.31 0.55 
Allergy 
medicines 
-0.13 -0.22 -0.05 -0.15 0.35 0.44 0.29 0.40 
Heart surgery -0.11 -0.11 -0.06 0.01 0.25 0.26 0.12 0.32 





-0.15 -0.29 -0.14 -0.25 0.33 0.47 0.26 0.45 
Acupuncture -0.07 -0.19 -0.12 -0.21 0.44 0.56 0.46 0.45 
*For risk perceptions, a negative value for a correlation indicates that a more positive word association is 
associated with belief that the treatment poses less risk. For benefit perceptions, a positive value for a correlation 
indicates that a more positive word association is associated with the treatment being more beneficial. 
